TransCode Therapeutics soars on positive results of therapy candidate for brain tumors

Transcode Therapeutics

25/09/2023 16:31

** Shares of drug developer TransCode Therapeutics Inc's
 RNAZ.O  triple to $1.99
    ** Co announces positive results with its lead therapeutic
candidate, TTX-MC138, against human glioblastoma multiforme
(GBM) - a malignant brain tumor - implanted in murine models 
    ** TTX-MC138 showed lasting activity and significantly
inhibited miRNA-10b, known to be a driver of tumor progression
in glioblastoma
    ** Co says TTX-MC138 could be used as a treatment for many
of these cancers, citing its efficacy in mouse models of
pancreatic and breast cancer
    ** Stock set to post best day ever
    ** Including session's gains, stock down 80%

 (Reporting by Sruthi Narasimha Chari in Bengaluru)
 ((Sruthinarasimha.chari@thomsonreuters.com))